Thomas Taapken
Director of Finance/CFO at INFLARX N.V.
Net worth: 4 865 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Per Svedenhag | M | 66 | 18 years | |
| Thomas Kronbach | M | 72 |
elbion AG
 elbion AG Miscellaneous Commercial ServicesCommercial Services elbion AG discovers and develops new small molecule drugs for the treatment of inflammatory and central nervous system diseases with high unmet medical need. It's lead product candidate AWD 12-281 is a topical inhibitor and is in phase IIa trials for the treatment of chronic obstructive pulmonary disease and has licensed it to GlaxoSmithKline for exclusive development and commercialization. It focuses on target areas, including PDE inhibitors and CNS modulators, in terms of novel chemistries, novel assays and mechanisms of action, as well as in-house animal disease models. Founded in 2002, the company is headquartered in Radebeul, Germany.
elbion NV
 elbion NV Pharmaceuticals: MajorHealth Technology Elbion NV discovers and develops therapeutics for neurological diseases and immunological disorders. It focuses on the discovery and development of new drugs for CNS and immunological diseases. The company was founded by Dr. Thomas Kronbach and Dr. Bernd Kastler in 2002 and is headquartered in Leuven, Belgium. | 22 years |
| Niels Riedemann | M | 51 | 17 years | |
| Tord Bertil Lendau | M | 67 |
Scibase AB
| 10 years |
| Gerd Zettlmeissl | M | 68 | 7 years | |
| Renfeng Guo | M | 53 | 17 years | |
| Helge Lubenow | M | 56 | 8 years | |
| Marie Gérard | F | - |
ImCyse SA
 ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 9 years |
| Nicolas Fulpius | M | 51 | 17 years | |
| Stig Gösta Ollmar | M | 78 | 26 years | |
| Christoph Esslinger | M | - |
Memo Therapeutics AG
 Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | 12 years |
| Maria Habel | M | 41 | 16 years | |
| Mark Kubler | M | 49 | 9 years | |
| Anthony Gibney | M | 53 | 3 years | |
| Ronald Scott | M | 69 | 7 years | |
| Denis Bedoret | M | 43 |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 4 years |
| Diana Ferro | F | 58 | 7 years | |
| Jvalini Dwarkasing | M | - | 3 years | |
| Richard Brudnick | M | 67 | 5 years | |
| Hege Hellstrom | M | 59 | 1 years | |
| Matt L. Leavitt | M | - | 3 years | |
| Frank Mathias | M | 62 | 6 years | |
| Dragan Grabulovski | M | - |
Memo Therapeutics AG
Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | - |
| Elias Papatheodorou | M | 55 |
Memo Therapeutics AG
Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | - |
| Michael Colérus | M | 62 | 10 years | |
| Linn Olsen | F | 47 | 4 years | |
| Daniel Vetter | M | - | 2 years | |
| Daniel Walker | M | - | 1 years | |
| Alf Laurell | M | - | - | |
| Nicole Bertsch | F | - | 3 years | |
| Christian Schmid | M | - | 3 years | |
| Petra Eßer | F | - | 3 years | |
| Stijn van Rompay | M | 48 |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 12 years |
| Robert Schier | M | - |
Memo Therapeutics AG
Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | - |
| Christina Franssen | M | - |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 5 years |
| Hugues Wallemacq | M | - |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 4 years |
| Pia Renaudin | F | 57 | 1 years | |
| Barbro Fridén | M | 68 |
Scibase AB
| - |
| Luc Philips | M | 73 |
elbion NV
elbion NV Pharmaceuticals: MajorHealth Technology Elbion NV discovers and develops therapeutics for neurological diseases and immunological disorders. It focuses on the discovery and development of new drugs for CNS and immunological diseases. The company was founded by Dr. Thomas Kronbach and Dr. Bernd Kastler in 2002 and is headquartered in Leuven, Belgium. | - |
| Stefan Yee | M | 62 |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 5 years |
| Erik van den Berg | M | 51 |
Memo Therapeutics AG
Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | 1 years |
| Jan Medina | M | - | - | |
| Vincent Brichard | M | - |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | - |
| Tobias Bergenblad | M | 51 | 9 years | |
| Bruce P. Burnett | M | - | 4 years | |
| Camilla Chong | M | 58 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Merja Tuulikki Karhapää | F | 62 | - | |
| William Burns | M | 76 | 5 years | |
| Peter John Fellner | M | 80 | 5 years | |
| Lars Klapproth | M | 56 |
Technical University of Berlin
| 6 years |
| Frank Hieronymi | M | 61 |
Technical University of Berlin
| 8 years |
| Pierre Vandepapeliere | M | - |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 4 years |
| Thomas Lennart Eklund | M | 57 | 2 years | |
| Florian Schmid | M | 50 | 4 years | |
| Philip Nelles | M | 50 |
Technical University of Berlin
| 6 years |
| Tong Zhang | M | 64 |
Technical University of Berlin
| 6 years |
| Per Gunnar Ernst Aniansson | M | 58 | 5 years | |
| Ismail Kola | M | 67 | - | |
| Uwe Bicker | M | 78 | - | |
| Guido Magni | M | 70 | - | |
| Achim Plum | M | 55 | 9 years | |
| Tilo Torsten Wigand Wolf | M | 60 |
Technical University of Berlin
| 11 years |
| Ann Hanham | M | 71 |
Burrill LLC
 Burrill LLC Investment ManagersFinance Burril LLC (Burrill) is a private equity/venture capital firm founded in 1994 by G. Steven. The firm is headquartered in San Francisco, California. | 13 years |
| Carsten Nils Erik Browall | M | 66 | - | |
| David Lemus | M | 61 | 1 years | |
| Bernd Kastler | M | 75 | - | |
| Simon James Grant | M | 57 | - | |
| Juha Heikki Tapio Jouhki | M | 58 | - | |
| Immo Querner | M | 61 |
Technical University of Berlin
| 7 years |
| Hartwig Grevener | M | 58 |
Technical University of Berlin
| 5 years |
| Evan S. Melrose | M | 54 |
Burrill LLC
Burrill LLC Investment ManagersFinance Burril LLC (Burrill) is a private equity/venture capital firm founded in 1994 by G. Steven. The firm is headquartered in San Francisco, California. | 2 years |
| Joachim Rautter | M | 62 |
Technical University of Berlin
| 3 years |
| Claudia Plath | F | 52 |
Technical University of Berlin
| 5 years |
| Carsten Heitkamp | M | 60 |
Technical University of Berlin
| 7 years |
| Marcus Behrendt | M | - |
Technical University of Berlin
| 6 years |
| Peer Reichelt | M | 53 |
Technical University of Berlin
| 7 years |
| Oliver Schlink | M | 54 |
Technical University of Berlin
| 4 years |
| Michael Sen | M | 55 |
Technical University of Berlin
| 3 years |
| Christoph Wollny | M | - |
Technical University of Berlin
| 8 years |
| Stefan Wintels | M | 58 |
Technical University of Berlin
| 4 years |
| Tim Dawidowsky | M | 57 |
Technical University of Berlin
| 4 years |
| Michaela Diener | M | - |
Technical University of Berlin
| 3 years |
| Samuel Hendrata Shantiawan | M | - |
Technical University of Berlin
| 4 years |
| Konstantin Alfred Winterstein | M | 55 |
Technical University of Berlin
| 4 years |
| Olivér Martin | M | - |
Technical University of Berlin
| 1 years |
| Andreas Klingen | M | 59 |
Technical University of Berlin
| 4 years |
| Christian Rhino | M | 55 |
Technical University of Berlin
| 4 years |
| Timo Hillebrand | M | - |
Technical University of Berlin
| 5 years |
| Thomas Diepold | M | 59 |
Technical University of Berlin
| 9 years |
| Mario Hermann Daberkow | M | 54 |
Technical University of Berlin
| 3 years |
| Christoph Steffens | M | 58 |
Technical University of Berlin
| 5 years |
| Sigrid Wattler | M | - |
Technical University of Berlin
| 3 years |
| Matthias Rumpelhardt | M | 64 |
Technical University of Berlin
| 3 years |
| Oliver Greve | M | 60 |
Technical University of Berlin
| 6 years |
| Shanjing Yao | M | 67 |
Technical University of Berlin
| 3 years |
| Zsolt Lisziewicz | M | - |
Technical University of Berlin
| 3 years |
| Kai Licha | M | 58 |
Technical University of Berlin
| 3 years |
| Solange Olszewska | F | - |
Technical University of Berlin
| 8 years |
| Marco Kisperth | M | 54 |
Technical University of Berlin
| 4 years |
| Jung Carsten | M | 57 |
Technical University of Berlin
| 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Germany | 60 | 60.00% |
| Sweden | 17 | 17.00% |
| Belgium | 10 | 10.00% |
| Finland | 9 | 9.00% |
| Switzerland | 5 | 5.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Thomas Taapken
- Personal Network
